Dementia represents a decline in cognitive function that impacts memory, thinking, and behavior, with Alzheimer’s disease accounting for 60-80% of cases. While current medications offer modest symptomatic relief, they don’t alter disease progression or restore cognitive function. Transcranial magnetic stimulation (TMS) offers a promising non-invasive approach to enhance cognitive functioning, slow cognitive decline, and improve quality of life for individuals with dementia. At Complete Mind Care of PA, our team of over 20 board-certified providers brings proven expertise from operating 35 Success TMS locations to deliver advanced neuromodulation treatments for cognitive enhancement near Philadelphia.
Remission is our mission. We understand the challenges facing individuals with cognitive impairment and their families, offering personalized treatment protocols with extended hours from 7 AM to 8 PM at our Horsham and Villanova locations throughout the Pennsylvania suburbs.
Specialized Cognitive Enhancement Expertise: Our providers understand the neurobiological mechanisms underlying cognitive decline and have extensive experience tailoring TMS protocols for individuals with neurodegenerative conditions.
Evidence-Based Protocols: We utilize research-backed TMS protocols targeting brain regions involved in memory, attention, and executive function, including the dorsolateral prefrontal cortex, temporoparietal cortex, and precuneus.
Success TMS Experience: Drawing on expertise from operating 35 Success TMS locations, our team has refined neuromodulation approaches and understands the nuances of treating complex cognitive presentations.
Comprehensive, Family-Centered Care: We work closely with patients and their families, coordinating care with neurologists, memory specialists, and other providers to ensure comprehensive support throughout the treatment journey.
Extended Accessibility: Office hours from 7 AM to 8 PM Monday-Thursday accommodate family caregivers’ schedules and provide flexible access to care throughout the Philadelphia area.
Dementia is not a single disease but an umbrella term describing a decline in cognitive abilities severe enough to interfere with daily functioning. Alzheimer’s disease, the most common form of dementia, is characterized by progressive memory impairment and decline across multiple cognitive domains.
Memory Impairment: Difficulty remembering recent events, conversations, or learned information; frequently repeating questions or statements; forgetting appointments or important dates.
Executive Function Deficits: Problems with planning, organizing, decision-making, problem-solving, and multitasking; difficulty following complex instructions or managing finances.
Language and Communication: Word-finding difficulties, trouble following or joining conversations, calling things by wrong names, or struggling to express thoughts.
Visuospatial Deficits: Getting lost in familiar places, difficulty judging distances, problems with visual perception, or trouble recognizing objects or faces.
Changes in Mood and Behavior: Depression, anxiety, apathy, social withdrawal, personality changes, or decreased interest in previously enjoyed activities.
Neurobiological Changes: Alzheimer’s disease involves progressive brain atrophy, accumulation of amyloid plaques and neurofibrillary tangles, neuronal loss, and synaptic dysfunction. These pathological changes affect neural networks involved in memory consolidation, attention, and executive function, particularly in the hippocampus, prefrontal cortex, and temporoparietal regions.
Transcranial Magnetic Stimulation is a non-invasive neuromodulation technique that uses focused magnetic fields to stimulate specific brain regions involved in cognition and memory. The magnetic field induces small electrical currents in targeted neurons, modulating their activity and promoting neuroplasticity—the brain’s ability to form new neural connections and reorganize existing networks.
For dementia treatment, TMS typically targets multiple brain regions over a treatment course, including the dorsolateral prefrontal cortex (involved in executive function and working memory), the temporoparietal cortex (involved in language and semantic memory), and the precuneus (a key hub of the brain’s default mode network critical for memory retrieval).
Important Note: TMS for dementia and Alzheimer’s disease is an investigational treatment and is not FDA-approved for these indications in the United States. While growing research demonstrates safety and promising cognitive benefits, this represents an off-label application of TMS technology. Deep TMS has received European CE certification for Alzheimer’s disease. Treatment is provided on a cash-pay basis and is not covered by insurance for cognitive enhancement or dementia.
TMS works through mechanisms similar to long-term potentiation, the cellular process underlying learning and memory. By delivering precisely targeted magnetic stimulation, TMS strengthens synaptic connections in brain regions affected by dementia, promoting adaptive neuroplasticity.
Alzheimer’s disease disrupts connectivity within the default mode network and other neural networks critical for cognition. TMS helps restore functional connectivity between brain regions, improving communication across cognitive networks.
Dementia is associated with altered patterns of cortical excitability—some regions become hypoactive while others show abnormal hyperactivity. TMS protocols use high-frequency stimulation to activate underactive regions and enhance their function.
TMS may activate compensatory neural pathways and recruit spared brain regions to support cognitive functions, helping the brain work more efficiently despite underlying pathology.
Emerging research suggests TMS may influence Alzheimer’s disease pathogenesis by modulating inflammatory processes, enhancing clearance of amyloid proteins, and promoting neuronal survival, though these mechanisms require further investigation.
Your journey begins with a comprehensive evaluation including cognitive testing, review of medical history, brain imaging if available, and discussion of treatment goals. We assess dementia severity, medication regimen, and suitability for TMS therapy.
Based on your cognitive profile, we develop an individualized TMS protocol targeting the brain regions most relevant to your specific pattern of impairment. Some protocols use neuronavigation with MRI or EEG to personalize stimulation parameters.
TMS sessions for dementia typically last 20-45 minutes depending on the protocol. You remain awake and alert, seated comfortably while the TMS coil is positioned over target brain regions. The device delivers magnetic pulses—you’ll hear clicking sounds and feel tapping sensations on your scalp.
Treatment protocols may involve:
Intensive Phase:
Maintenance Phase:
Research demonstrates that combining TMS with concurrent cognitive training produces superior outcomes compared to TMS alone. We can coordinate with cognitive rehabilitation specialists to integrate brain training exercises during or after TMS sessions.
We track cognitive improvement using validated assessment scales (ADAS-Cog, MMSE, CDR) and functional measures (activities of daily living). We also obtain feedback from family members regarding observed changes in memory, behavior, and daily functioning.
Meta-Analyses Confirm Cognitive Benefits: Multiple meta-analyses demonstrate that repetitive TMS significantly improves global cognitive functioning in mild-to-moderate Alzheimer’s disease patients, with effect sizes indicating clinically meaningful benefits.
Large-Scale Randomized Controlled Trials: A 2024 multisite double-blind RCT investigated TMS efficacy over multiple dose durations, with assessments up to 6 months post-treatment showing sustained cognitive improvements in actively treated patients.
Precuneus Targeting Shows Slowing of Decline: A landmark 2022 study published in Brain (Oxford Academic) demonstrated that 24 weeks of personalized rTMS targeting the precuneus slowed cognitive and functional decline in Alzheimer’s patients. A follow-up 52-week trial (2025) showed continued benefits with maintenance stimulation, with active treatment group declining significantly less than sham group.
Combined TMS + Cognitive Training: A 131-patient randomized trial showed 31.7% of participants receiving TMS plus cognitive training achieved clinically significant improvement (≥4-point ADAS-Cog improvement) versus 15.4% in the sham group.
Optimal Protocol Parameters: Research indicates that high-frequency (20 Hz) stimulation, targeting multiple brain sites, treatment courses >10 sessions, and combining TMS with cognitive training produce the most robust benefits.
Best Outcomes in Mild-to-Moderate Disease: Studies consistently show that patients with mild-to-moderate dementia (MMSE 18-26) respond better to TMS than those with severe impairment, supporting earlier intervention.
Sustained Effects: Follow-up studies demonstrate cognitive benefits lasting 3-6 months after intensive treatment courses, with maintenance stimulation extending benefits further.
Safety Profile: Extensive research confirms TMS safety in older adults with dementia, with minimal side effects and no acceleration of disease progression.
No. TMS is FDA-cleared for major depressive disorder and OCD, but its use for dementia is investigational and off-label in the United States. However, Deep TMS has received European CE certification for Alzheimer’s disease, and extensive research supports its safety and potential cognitive benefits.
Research shows improvements in global cognitive functioning, memory (both short-term and long-term recall), attention, language functions, and executive abilities like planning and problem-solving. Patients and families also report improvements in activities of daily living and behavioral symptoms.
Research indicates that individuals with mild-to-moderate dementia (MMSE scores 18-26) respond best to TMS. Those with higher education levels, younger age, and earlier-stage disease tend to show greater benefits. Severe dementia is less responsive to current TMS protocols.
Studies show cognitive benefits lasting 3-6 months after intensive treatment courses. However, research increasingly supports ongoing maintenance stimulation (weekly sessions) to sustain and potentially extend benefits over longer periods.
Yes. Extensive research confirms TMS safety in older adults with cognitive impairment. The most common side effects are mild headache and scalp discomfort. Seizure risk is extremely rare, and TMS does not accelerate disease progression.
No. Because TMS for dementia is not FDA-approved, insurance does not cover this treatment. We offer cash-pay options and can discuss financing through CareCredit or payment plans to make treatment accessible.
Yes. Research shows TMS benefits extend beyond cognition to include improvements in mood, reduced anxiety and depression, and decreased behavioral disturbances like apathy and agitation—all common in dementia.
Disclaimer: TMS for dementia and Alzheimer’s disease is an investigational treatment approach and is not FDA-approved for these indications in the United States. Deep TMS has received European CE certification for Alzheimer’s disease. Individual results vary significantly, and cognitive benefits are generally modest rather than curative. This treatment should be viewed as complementary to, not a replacement for, standard dementia care including medications and cognitive/behavioral interventions. Treatment is provided on a cash-pay basis and is not covered by insurance. This information is for educational purposes and does not constitute medical advice. Consult with qualified healthcare providers specializing in dementia care to determine if TMS is appropriate for your situation.
Conditions Treated
721 Dresher Rd # 1100, Horsham, PA 19044
Complete Mind Care was founded on the premise of providing full mental health support delivered by a team of expert professionals, in the comfort of a world-class facility local to you—so you can build a foundation for lasting recovery close to home. Plus 40+ additional insurance carriers accepted.
Don’t see your insurance listed? Call our office at 215-607-7250 or 215-918-7939 to verify coverage.
